Timo Grimmon
About Timo Grimmon
Timo Grimmon serves as the Downstream Team Leader at MeiraGTx in London, England, where he has worked since 2021. He has a background in biotechnology and has held various roles in the field, including contributions to the Covid-19 vaccine development.
Work at MeiraGTx
Timo Grimmon has been serving as the Downstream Team Leader at MeiraGTx since 2021. In this role, he coordinates and plans all downstream and final filling activities, ensuring compliance with safety regulations. Prior to his current position, he worked as a Senior Bioprocessing Scientist at MeiraGTx for six months in 2021. His experience at MeiraGTx includes working with the Lentivector® platform, which is integral to gene therapy treatments.
Education and Expertise
Timo Grimmon earned a Master of Science (M.Sc.) in Biotechnology from The University of Manchester, where he studied from 2014 to 2018. His educational background also includes achieving 34 IB Points in the International Baccalaureate program at Nanjing International School from 2010 to 2014. This academic foundation supports his expertise in bioprocessing and gene therapy.
Background
Before joining MeiraGTx, Timo Grimmon held various positions in the biotechnology field. He worked as a Biotechnologist Team Leader at Oxford Biomedica from 2020 to 2021. Additionally, he gained experience as a Freelance Translator at BASF-YPC COMPANY LIMITED in Nanjing, China, from 2012 to 2014. He also contributed to a start-up focused on pollution filtration masks at Nanjing International School during the same period.
Achievements
Timo Grimmon contributed to the manufacture of the Covid2019 vaccine in partnership with AstraZeneca. His involvement in this significant project highlights his role in advancing public health through biotechnology. His work with the Lentivector® platform further underscores his contributions to gene therapy treatments.